Editorials

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?

Hematology and Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
University College London, London, UK
UNITO Dipartimento di Oncologia, University of Turin, Turin, Italy
Hematology and Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
Vol. 104 No. 11 (2019): November, 2019 https://doi.org/10.3324/haematol.2019.228684